A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

Patient achieving HbA1c below 7.0% (Yes /No)

Count of patient(s)

Time frame: Year 1

Patient achieving HbA1c below or equal to 6.5% (Yes/No)

Count of patient(s)

Time frame: Year 1

Patient achieving HbA1c below 7.0% or at least 1.0%-point reduction in HbA1c (Yes/No)

Count of patient(s)

Time frame: From randomization to year 1

Patient achieving greater than or equal to 5% reduction in body weight (Yes/No)

Count of patient(s)

Time frame: From randomization to year 1

Patient achieving individualized HbA1c target per Healthcare Effectiveness Data and Information Set (HEDIS) criteria (below 8.0% if age greater than or equal to 65 years or with defined comorbidities or otherwise below 7.0%) (Yes/No)

Count of patient(s)

Time frame: Year 1

Patient achieving HbA1c less than or equal to treatment provider defined individualized target (Yes/No)

Count of patient(s)

Time frame: Year 1

Relative change in body weight (%)

Percentage

Time frame: From randomization to year 1

Change in body weight (lbs)

Lbs

Time frame: From randomization to year 1

Time to treatment intensification (add-on) or change (switch)

Days

Time frame: From randomization to year 1

Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Relative treatment satisfaction total score

Score on a scale (The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) will be used to measure the change in patient satisfaction with their diabetes treatment. It consists of a six-item scale assessing treatment satisfaction and two items assessing perceived frequency of hyperglycaemia and hypoglycaemia. The DTSQc items are on a scale from 3 to -3. If they experience no change, then 0 is chosen. Higher score indicate higher satisfaction with their current treatment)

Time frame: Year 1